Limitation and potential hazards of MAOI's for the treatment of depressive symptoms in abstinent alcoholics.
Schottenfeld
R S
RS
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519.
O'Malley
S S
SS
Smith
L
L
Rounsaville
B J
BJ
Jaffe
J H
JH
D000328:Adult; D000437:Alcoholism / Q000150:complications* / Q000534:rehabilitation; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D010624:Phenelzine / Q000009:adverse effects; D011567:Psychiatric Department, Hospital; D011569:Psychiatric Status Rating Scales; D011897:Random Allocation; D013695:Temperance; D014191:Tranylcypromine / Q000009:adverse effects
D008996:Monoamine Oxidase Inhibitors; D014191:Tranylcypromine; D010624:Phenelzine